Barclays
LYEL icon

Barclays’s Lyell Immunopharma LYEL Stock Holding History

Barclays’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$58.9K Buy
6,013
+1,298
+28% +$17.3K ﹤0.01% 4517
2026
Q2 		$66.2K Buy
4,715
+3,044
+182% +$55.1K ﹤0.01% 4222
2026
Q1 		$33.5K Sell
1,671
-14,296
-90% -$334K ﹤0.01% 4444
2025
Q4 		$491K Buy
15,967
+14,775
+1,240% +$331K ﹤0.01% 3854
2025
Q3 		$19.4K Buy
1,192
+37
+3% +$423 ﹤0.01% 4938
2025
Q2 		$10.2K Sell
1,155
-8,018
-87% -$73.1K ﹤0.01% 4913
2025
Q1 		$98.7K Sell
9,173
-3,746
-29% -$45.9K ﹤0.01% 4415
2024
Q4 		$165K Buy
12,919
+888
+7% +$17.6K ﹤0.01% 4391
2024
Q3 		$332K Buy
12,031
+9,116
+313% +$268K ﹤0.01% 4025
2024
Q2 		$84.5K Sell
2,915
-4,412
-60% -$210K ﹤0.01% 3985
2024
Q1 		$327K Sell
7,327
-5,827
-44% -$250K ﹤0.01% 3845
2023
Q4 		$510K Buy
13,154
+892
+7% +$32.1K ﹤0.01% 3859
2023
Q3 		$361K Buy
12,262
+2,349
+24% +$112K ﹤0.01% 2986
2023
Q2 		$630K Sell
9,913
-2,350
-19% -$130K ﹤0.01% 2605
2023
Q1 		$579K Sell
12,263
-4,507
-27% -$241K ﹤0.01% 3163
2022
Q4 		$1.16M Buy
16,770
+10,035
+149% +$997K ﹤0.01% 2681
2022
Q3 		$988K Buy
6,735
+6,301
+1,452% +$853K ﹤0.01% 2244
2022
Q2 		$57K Sell
434
-1,198
-73% -$122K ﹤0.01% 3988
2022
Q1 		$164K Buy
+1,632
New +$198K ﹤0.01% 3541

Other funds holding LYEL

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Barclays's LYEL Position: Q3 2026 in Review

Barclays increased its Lyell Immunopharma (LYEL) stake by 28% in Q3 2026, buying an estimated $17.3K and bringing the position to 6,013 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4517.

Barclays first reported a position in LYEL in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.16M in Q4 2022. 31 funds tracked by Wall St. Rank hold LYEL as of Q3 2026.

  • Barclays held 6,013 shares of Lyell Immunopharma worth $58.9K as of Q3 2026.
  • Barclays bought 1,298 Lyell Immunopharma shares in Q3 2026, an estimated $17.3K.
  • Lyell Immunopharma made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4517 holding.
  • Barclays first reported a position in Lyell Immunopharma in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Lyell Immunopharma position peaked at $1.16M in Q4 2022.
  • 31 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.